MA53741A - Procédés de traitement de troubles myéloprolifératifs - Google Patents
Procédés de traitement de troubles myéloprolifératifsInfo
- Publication number
- MA53741A MA53741A MA053741A MA53741A MA53741A MA 53741 A MA53741 A MA 53741A MA 053741 A MA053741 A MA 053741A MA 53741 A MA53741 A MA 53741A MA 53741 A MA53741 A MA 53741A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- myeloproliferative disorders
- treating myeloproliferative
- treating
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862736369P | 2018-09-25 | 2018-09-25 | |
US201862783076P | 2018-12-20 | 2018-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53741A true MA53741A (fr) | 2021-08-04 |
Family
ID=69950867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053741A MA53741A (fr) | 2018-09-25 | 2019-09-24 | Procédés de traitement de troubles myéloprolifératifs |
Country Status (13)
Country | Link |
---|---|
US (2) | US20220031699A1 (fr) |
EP (1) | EP3856169A4 (fr) |
JP (1) | JP2022502492A (fr) |
KR (1) | KR20210102192A (fr) |
CN (1) | CN113286584A (fr) |
AU (1) | AU2019346521A1 (fr) |
BR (1) | BR112021005518A2 (fr) |
CL (1) | CL2021000744A1 (fr) |
IL (1) | IL281736A (fr) |
MA (1) | MA53741A (fr) |
MX (2) | MX2021003450A (fr) |
SG (1) | SG11202103019WA (fr) |
WO (1) | WO2020068755A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3856189A4 (fr) * | 2018-09-25 | 2022-06-29 | Impact Biomedicines, Inc. | Procédés de traitement de troubles myéloprolifératifs |
BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
WO2022132933A1 (fr) | 2020-12-16 | 2022-06-23 | Impact Biomedicines, Inc. | Dosage de fédratinib |
MX2023009858A (es) | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
WO2023044297A1 (fr) | 2021-09-14 | 2023-03-23 | Impact Biomedicines, Inc. | Fédratinib pour traiter des troubles myéloprolifératifs |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20090093009A1 (en) * | 2007-10-09 | 2009-04-09 | Sum Chan | Mass spectrometry method for measuring thiamine in body fluid |
WO2012060847A1 (fr) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions et procédés de traitement de la myélofibrose |
US20130102624A1 (en) * | 2011-05-19 | 2013-04-25 | John V. Schloss | Early detection of thiamine deficiency |
US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
US20150148345A1 (en) | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
CA2936865A1 (fr) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Derives de diaminopyrimidine benzenesulfone et leurs utilisations |
WO2017024171A1 (fr) * | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Procédés de traitement de syndrome myéloprolifératif |
BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
EP3856189A4 (fr) | 2018-09-25 | 2022-06-29 | Impact Biomedicines, Inc. | Procédés de traitement de troubles myéloprolifératifs |
KR20210145735A (ko) | 2019-02-12 | 2021-12-02 | 임팩트 바이오메디신스, 인코포레이티드 | Jak2 저해제의 결정질 형태 |
FR3092581A1 (fr) | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
-
2019
- 2019-09-24 BR BR112021005518-5A patent/BR112021005518A2/pt unknown
- 2019-09-24 SG SG11202103019WA patent/SG11202103019WA/en unknown
- 2019-09-24 MA MA053741A patent/MA53741A/fr unknown
- 2019-09-24 CN CN201980070403.4A patent/CN113286584A/zh active Pending
- 2019-09-24 MX MX2021003450A patent/MX2021003450A/es unknown
- 2019-09-24 KR KR1020217012234A patent/KR20210102192A/ko unknown
- 2019-09-24 US US17/279,765 patent/US20220031699A1/en active Pending
- 2019-09-24 WO PCT/US2019/052608 patent/WO2020068755A1/fr active Application Filing
- 2019-09-24 EP EP19866319.7A patent/EP3856169A4/fr active Pending
- 2019-09-24 JP JP2021540380A patent/JP2022502492A/ja active Pending
- 2019-09-24 AU AU2019346521A patent/AU2019346521A1/en active Pending
-
2021
- 2021-03-22 IL IL281736A patent/IL281736A/en unknown
- 2021-03-24 MX MX2023013844A patent/MX2023013844A/es unknown
- 2021-03-25 CL CL2021000744A patent/CL2021000744A1/es unknown
- 2021-12-23 US US17/560,373 patent/US11400092B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2022502492A (ja) | 2022-01-11 |
US11400092B2 (en) | 2022-08-02 |
EP3856169A1 (fr) | 2021-08-04 |
US20220031699A1 (en) | 2022-02-03 |
MX2023013844A (es) | 2023-12-08 |
AU2019346521A1 (en) | 2021-05-20 |
CL2021000744A1 (es) | 2021-10-08 |
SG11202103019WA (en) | 2021-04-29 |
IL281736A (en) | 2021-05-31 |
US20220133724A1 (en) | 2022-05-05 |
EP3856169A4 (fr) | 2022-06-29 |
BR112021005518A2 (pt) | 2021-06-29 |
CN113286584A (zh) | 2021-08-20 |
MX2021003450A (es) | 2021-07-16 |
KR20210102192A (ko) | 2021-08-19 |
WO2020068755A1 (fr) | 2020-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
MA50056A (fr) | Procédés de traitement de tumeur | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA47095A (fr) | Traitement du palais mou | |
MA45192A (fr) | Traitement d'association | |
MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA44234A (fr) | Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA47212A (fr) | Méthodes de traitement de troubles neurologiques | |
MA51525A (fr) | Traitement de minéraux | |
MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
MA42930A (fr) | Traitement de maladies neurodégénératives | |
MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
MA54880A (fr) | Compositions et procédés de traitement de troubles neurocognitifs | |
MA52199A (fr) | Compositions et procédés de traitement de la dystrophie maculaire |